Skip to main content

Video commentaries

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Expert commentaries on the latest practice-influencing developments from international congresses.

ESMO 2018 Congress

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

30-10-2018 | Colorectal cancer | ESMO 2018 | Video

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC

Heinz-Josef Lenz outlines the results of CheckMate-142 study investigating combination immunotherapy in the first-line treatment of patients with MSI-high metastatic colorectal cancer, and discusses the unmet needs of those with MSI-low tumors (5:58).

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial

ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

24-10-2018 | Tamoxifen | ESMO 2018 | Video

Serum analysis sheds light on tamoxifen adherence

Barbara Pistilli discusses the CANTO COMPLETE study of premenopausal breast cancer patient adherence to endocrine therapy (4:31).

24-10-2018 | Breast cancer | ESMO 2018 | Video

Evaluating alpelisib addition to standard of care in SOLAR-1

We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

23-10-2018 | Ovarian cancer | ESMO 2018 | Video

SOLO1 trial of maintenance olaparib in advanced ovarian cancer

SOLO1 co-author Susana Banerjee provides a quick take on the study findings and discusses the challenges going forward (3:55).

22-10-2018 | Non-small cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

2018 ASCO Annual Meeting

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Neoadjuvant chemoradiotherapy beneficial for resectable pancreatic cancer

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)

Watch the accompanying expert commentary.

08-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: An update from ASCO 2018 on targeted therapies in lung cancer

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Adjuvant mFOLFIRINOX shows benefits over gemcitabine in pancreatic cancer

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58).

Read the related news story

Watch the accompanying expert commentary

07-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: Lung cancer research from ASCO 2018

Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).

06-06-2018 | Gastrointestinal cancers | ASCO 2018 | Video

Expert commentary: GI highlights including the PRODIGE 7, PRODIGE 24, and PREOPANC trials

ASCO expert Andrew Epstein gives his account of some of the key trial findings in  gastointestinal cancer from this year's meeting (9:05).

06-06-2018 | Esophageal cancer | ASCO 2018 | Video

Researcher comment: Shedding light on the use of PPIs and aspirin in patients with Barrett’s esophagus

Janusz Jankowski discusses his team's findings from the AspECT study on the chemoprevention efficacy and safety of aspirin and esomeprazole in esophageal cancer (7:42). 

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

03-06-2018 | Head and neck cancers | ASCO 2018 | Video

Expert commentary: Are women with head and neck cancer undertreated?

ASCO expert Joshua Jones comments on the outcomes of an analysis of cancer registry data from a California Hospital system that highlights a disparity in intensive treatment between men and women with head and neck cancer (2:57).

Read the accompanying news story here.

image credits